HEXTEND AND PENTALYTE CHINA LICENSE AGREEMENT BETWEEN BIOTIME, INC. AND SUMMIT PHARMACEUTICALS INTERNATIONAL CORPORATIONHextend and Pentalyte China License Agreement • March 30th, 2006 • Biotime Inc • Biological products, (no disgnostic substances) • California
Contract Type FiledMarch 30th, 2006 Company Industry JurisdictionThis License Agreement, dated as of March 24, 2006, sets forth the terms under which BioTime Inc. (“BioTime”) grants Summit Pharmaceuticals International Corporation (“Summit”) the rights to develop and commercialize Hextend and PentaLyte in China and Taiwan.